JP2020533344A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533344A5
JP2020533344A5 JP2020514518A JP2020514518A JP2020533344A5 JP 2020533344 A5 JP2020533344 A5 JP 2020533344A5 JP 2020514518 A JP2020514518 A JP 2020514518A JP 2020514518 A JP2020514518 A JP 2020514518A JP 2020533344 A5 JP2020533344 A5 JP 2020533344A5
Authority
JP
Japan
Prior art keywords
igf
months
agonist
analog
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514518A
Other languages
English (en)
Japanese (ja)
Other versions
JP7819893B2 (ja
JP2020533344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050427 external-priority patent/WO2019051474A1/en
Publication of JP2020533344A publication Critical patent/JP2020533344A/ja
Publication of JP2020533344A5 publication Critical patent/JP2020533344A5/ja
Priority to JP2023125304A priority Critical patent/JP2023145646A/ja
Priority to JP2025086115A priority patent/JP2025114869A/ja
Application granted granted Critical
Publication of JP7819893B2 publication Critical patent/JP7819893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514518A 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物 Active JP7819893B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023125304A JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
US62/557,113 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023125304A Division JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020533344A JP2020533344A (ja) 2020-11-19
JP2020533344A5 true JP2020533344A5 (cg-RX-API-DMAC10.html) 2021-11-11
JP7819893B2 JP7819893B2 (ja) 2026-02-25

Family

ID=63794620

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020514518A Active JP7819893B2 (ja) 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物
JP2023125304A Pending JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A Pending JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023125304A Pending JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A Pending JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Country Status (25)

Country Link
US (3) US20190151411A1 (cg-RX-API-DMAC10.html)
EP (3) EP3681602B1 (cg-RX-API-DMAC10.html)
JP (3) JP7819893B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200097679A (cg-RX-API-DMAC10.html)
CN (1) CN111432881A (cg-RX-API-DMAC10.html)
AU (2) AU2018328827B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020004760A2 (cg-RX-API-DMAC10.html)
CA (1) CA3075482A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020000597A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020004244A2 (cg-RX-API-DMAC10.html)
DK (1) DK3681602T3 (cg-RX-API-DMAC10.html)
EA (1) EA202090705A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP20055797A (cg-RX-API-DMAC10.html)
ES (1) ES3075637T3 (cg-RX-API-DMAC10.html)
IL (1) IL273174B2 (cg-RX-API-DMAC10.html)
LT (1) LT3681602T (cg-RX-API-DMAC10.html)
MX (1) MX421623B (cg-RX-API-DMAC10.html)
MY (1) MY204825A (cg-RX-API-DMAC10.html)
PE (1) PE20201166A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020500489A1 (cg-RX-API-DMAC10.html)
PT (1) PT3681602T (cg-RX-API-DMAC10.html)
SG (1) SG11202002088TA (cg-RX-API-DMAC10.html)
UA (1) UA128690C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019051474A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202001568B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
KR20230113287A (ko) * 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
CA3248280A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited POLYTHERAPY FOR PREMATURE INFANTS
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
EP0956041A1 (en) 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US20020028764A1 (en) 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
CA2429615C (en) 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
WO2004113382A1 (en) 2003-06-13 2004-12-29 Insmed, Inc. Recombinant igf expression systems
CA2899824A1 (en) 2004-12-24 2006-06-29 Insmed, Inc. Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
RU2558821C2 (ru) 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
US9168289B2 (en) 2011-02-01 2015-10-27 Mor Research Applications Ltd. Method of treatment of small for gestational age infants under two years of age
CA2897062A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Lyophilization process
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd

Similar Documents

Publication Publication Date Title
FI3328416T3 (fi) C-tyypin natriureettisten peptidivarianttien käyttö luuston dysplasian hoidossa
US20250000933A1 (en) Terlipressin compositions and their methods of use
JP2018504420A5 (cg-RX-API-DMAC10.html)
JP2010524928A5 (cg-RX-API-DMAC10.html)
EP3347032B1 (en) Terlipressin for the treatment of ascites due to liver cirrhosis administered as a continuous infusion
US9370535B2 (en) Method for treatment of advanced solid tumors
CA2940835A1 (en) Medicine against growth failure induced by administration of steroid
AU2024227601B2 (en) Methods and compositions for treating chronic lung diseases
JP2025114869A5 (cg-RX-API-DMAC10.html)
JP2024529452A5 (cg-RX-API-DMAC10.html)
CN118234504A (zh) 治疗剂的口服递送
CA2543507A1 (en) Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
JP2016535015A5 (cg-RX-API-DMAC10.html)
CN113646327A (zh) 用于治疗肝脏疾病的ghrh或其类似物
CN101001638A (zh) 用于预防和控制胰岛素诱发的低血糖的组合物和方法
JP2015524808A5 (cg-RX-API-DMAC10.html)
JP2015524432A5 (cg-RX-API-DMAC10.html)
JP4053107B2 (ja) 血小板減少症の予防剤および治療剤
TH2001001388A (th) วิธีการและองค์ประกอบสำหรับการบำบัดโรคปอดเรื้อรัง
JP2007513059A5 (cg-RX-API-DMAC10.html)
Rodríguez-Castaño et al. Oral sildenafil for severe pulmonary hypertension developing after ibuprofen use in a neonate.
Dailey Developing a pulmonary insulin delivery system for patients with diabetes
WO2025129029A2 (en) Combinations of foralumab with glucagon-like peptide 1 (glp-1) agonists or sodium-glucose cotransporter-2 (sglt2) inhibitors and methods of use thereof
CN110179970A (zh) Il-1r2细胞因子在制备治疗肝功能衰竭药剂中的应用
HK40014065A (en) Terlipressin composition for use in treating ascites